Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Peds Ocd

903 views

Published on

Published in: Health & Medicine, Sports
  • Login to see the comments

Peds Ocd

  1. 1. Pharmacotherapy for Pediatric OCD A Systematic Review
  2. 2. Objectives <ul><li>Review randomized placebo-controlled trials in pediatric OCD </li></ul><ul><li>Discuss a published meta-analysis of SSRIs in pediatric OCD </li></ul>
  3. 3. Method <ul><li>OVID Medline 1950 to December 2007: </li></ul><ul><ul><li>Child [MeSH] or Adolescent [MeSH] or pediatric [keyword] or paediatric [keyword] </li></ul></ul><ul><ul><li>AND </li></ul></ul><ul><ul><li>Obsessive-Compulsive Disorder [MeSH] </li></ul></ul><ul><li>Resulted in 2453 hits </li></ul>
  4. 4. Inclusion Criteria <ul><li>Randomized placebo-controlled trial </li></ul><ul><li>Subjects aged 0-18 with DSM diagnosis of Obsessive-Compulsive disorder </li></ul><ul><li>Intervention is pharmacological </li></ul><ul><li>English language </li></ul><ul><li>Parallel or Cross-over design </li></ul>
  5. 5. Exclusion Criteria <ul><li>Less than 30 subjects for parallel design, less than 15 for cross-over </li></ul><ul><li>Principal diagnosis of Tourette’s Disorder or Developmental Disorder </li></ul>
  6. 6. Child Yale-Brown Obsessive Compulsive Scale <ul><li>C-YBOCS: </li></ul><ul><ul><li>10 item scale, range of 0-4 </li></ul></ul><ul><ul><ul><li>Obsessions and Compulsions </li></ul></ul></ul><ul><ul><ul><li>Time occupied, Interference, Distress, Personal Control, Resistance </li></ul></ul></ul><ul><ul><li>Range of scale 0-40 </li></ul></ul><ul><ul><li>8-15 is mild, 16-23 moderate, >24 severe </li></ul></ul>
  7. 7. Clomipramine (Anafranil)
  8. 8. Clomipramine <ul><li>DeVeaugh et al, 1992 </li></ul><ul><li>Subjects: 10-17 years </li></ul><ul><li>CMI started at 25mg/d, titrated up to 75mg/d by second week, then titrated to 200mg/d (or 3mg/kg/d) </li></ul><ul><li>N=60, 31 had CMI vs. 29 PBO </li></ul><ul><li>Duration: 2 weeks of PBO lead-in, then 8 week trial </li></ul>
  9. 9. Clomipramine
  10. 10. Clomipramine <ul><li>One year open-label extension: 25/47 of subjects continuing to use CMI </li></ul>
  11. 11. Clomipramine Tremor Fatigue Dizziness Somnolence Dry Mouth 2.3% 32.6% 9.1% 34.8% 13.6% 41.3% 11.4% 45.7% 15.9% 63.0% PBO (N=29) CMI (N=31)
  12. 12. Clomipramine 0 1 subj. Hepatic Enzyme Inc. 2.3% 13.0% Dyspepsia 2.3% 21.7% Anorexia 2.3% 21.7% Constipation PBO (N=29) CMI (N=31)
  13. 13. Clomipramine <ul><li>Limits: </li></ul><ul><ul><li>Side effects of CMI compromises blinding </li></ul></ul><ul><ul><li>Small sample size </li></ul></ul><ul><ul><li>No mention of suicidal ideation </li></ul></ul><ul><ul><li>Sponsored by Ciba-Geigy </li></ul></ul>
  14. 14. Fluoxetine (Prozac)
  15. 15. Fluoxetine (1) <ul><li>Geller et al, 2001 </li></ul><ul><li>Subjects: 7-17 </li></ul><ul><li>FLX started at 10mg/d, titrated up to 20-60mg/d </li></ul><ul><li>N=103, 71 had FLX vs. 32 PBO </li></ul><ul><li>Duration: 13 weeks </li></ul>
  16. 16. Fluoxetine (1)
  17. 17. Fluoxetine (1) <ul><li>Effect Size = 0.5 </li></ul><ul><li>Mean dose of FLX was 24.6mg </li></ul><ul><li>Effects comparable between children and adolescents </li></ul>
  18. 18. Fluoxetine (1) <ul><li>No adverse effect that was significantly different from placebo </li></ul><ul><li>Diarrhea and Hyperkinesia found more in Fluoxetine group </li></ul>
  19. 19. Fluoxetine (1) <ul><li>Limits: </li></ul><ul><ul><li>Many subjects dropped out </li></ul></ul><ul><ul><ul><li>31% of FLX, 37.5% of PBO </li></ul></ul></ul><ul><ul><ul><li>No difference in reasons for drop out </li></ul></ul></ul><ul><ul><li>Sponsored by Eli Lilly </li></ul></ul>
  20. 20. Fluoxetine (2) <ul><li>Liebowitz et al, 2002 </li></ul><ul><li>Subjects: 6-18 years old </li></ul><ul><li>FLX 20mg/d titrated up to 80mg/d </li></ul><ul><li>N=43, 21 had FLX, 22 had PBO </li></ul><ul><li>Duration: 8 weeks + 8 weeks of maintenance for responders </li></ul>
  21. 21. Fluoxetine (2)
  22. 22. Fluoxetine (2) <ul><li>Significant difference only in maintenance extension </li></ul><ul><li>Mean dose of FLX 64.8mg/d </li></ul>
  23. 23. Fluoxetine (2) 4.5% 33.3% Muscle Ache 0% 28.6% Nightmares 4.5% 38.1% Drowsiness 4.5% 33.3% Weight loss 0% 19% Palpitations PBO (N=22) FLX (N=21)
  24. 24. Fluoxetine (2) <ul><li>Significance only found on post-hoc analysis of extension group </li></ul><ul><li>Sponsored by Eli Lilly and NIMH </li></ul>
  25. 25. Paroxetine (Paxil)
  26. 26. Paroxetine <ul><li>Geller et al, 2004 </li></ul><ul><li>Subjects: 7-17 </li></ul><ul><li>PRX:started at 10mg/d, titrated up to 50mg/d </li></ul><ul><li>N=203: 98 had PRX, 105 had PBO </li></ul><ul><li>Duration: 10 weeks </li></ul>
  27. 27. Paroxetine
  28. 28. Paroxetine <ul><li>Stronger effect in more severe OCD </li></ul><ul><li>Stronger effect in younger age </li></ul><ul><li>Mean dose: 20mg/d for children, 26.8mg/d for adolescents </li></ul>
  29. 29. Paroxetine 2% 8% Diarrhea 1% 9% Hostility 1% 9% Decreased appetite 3% 10% Trauma (?) 6% 12% Hyperkinesia PBO N=105 PRX N=98
  30. 30. Paroxetine 0 1 subj. Suicidal Ideation (?situation) 1% 5% Neurosis (?) 2% 5% Agitation 2% 6% Vomiting 1% 8% Asthenia PBO N=105 PRX N=98
  31. 31. Paroxetine <ul><li>Limits: </li></ul><ul><ul><li>High drop out rate (in children only) </li></ul></ul><ul><ul><ul><li>33% of PRX vs. 24% of PBO </li></ul></ul></ul><ul><ul><li>Sponsored by GlaxoSmithKline </li></ul></ul>
  32. 32. Fluvoxamine (Luvox)
  33. 33. Fluvoxamine <ul><li>Riddle et al, 2001 </li></ul><ul><li>Subjects: 8-17 years old </li></ul><ul><li>FLV started at 25mg qhs, titrated up to 100mg bid (200mg/d) </li></ul><ul><li>N=120, 57 had FLV, 63 had PBO </li></ul><ul><li>Duration: 10 weeks </li></ul>
  34. 34. Fluvoxamine
  35. 35. Fluvoxamine <ul><li>Higher response in younger age </li></ul><ul><li>Statistically significant differences between groups as early as week 1 </li></ul><ul><li>Mean dose was 165mg/d </li></ul>
  36. 36. Fluvoxamine 15.9% 26.3% Asthenia (mean onset ~20d) 9.5% 29.8% Insomnia (mean onset at 45d) PBO N=63 FLV N=57
  37. 37. Fluvoxamine <ul><li>Limits: </li></ul><ul><ul><li>Many dropouts: </li></ul></ul><ul><ul><ul><li>33% of FLV vs. 43% of PBO </li></ul></ul></ul><ul><ul><li>Sponsored by Solvay </li></ul></ul>
  38. 38. Sertraline (Zoloft)
  39. 39. Sertraline (1) <ul><li>March et al 1998 </li></ul><ul><li>Subjects: 6-17 </li></ul><ul><li>Sertraline started at 25mg/d, titrated up to 50-200mg </li></ul><ul><li>N=187: 92 had SRT, 95 had PBO </li></ul><ul><li>Duration: 1 week PBO lead-in, 12 week trial </li></ul>
  40. 40. Sertraline (1)
  41. 41. Sertraline (1) <ul><li>Mean dose of SRT was 167mg/d </li></ul>
  42. 42. Sertraline (1) 0% 7% Tremor 2% 13% Agitation 7% 17% Nausea 13% 37% Insomnia PBO N=95 SRT N=92
  43. 43. Sertraline (1) <ul><li>Limits: </li></ul><ul><ul><li>12/92 withdrew from SRT due to adverse events vs. 3/95 in PBO </li></ul></ul><ul><ul><li>Sponsored by Pfizer </li></ul></ul>
  44. 44. Sertraline (2) <ul><li>Pediatric OCD Treatment Study (POTS), 2004 </li></ul><ul><li>Subjects: 7-17 </li></ul><ul><li>Sertraline: 25mg/d up to 200mg/d </li></ul><ul><li>N=112: 28 had SRT+CBT, 28 had CBT, 28 had SRT, 28 had PBO </li></ul>
  45. 45. Sertraline (2)
  46. 46. Sertraline (2)
  47. 47. Sertraline (2) <ul><li>Effect size compared to placebo: </li></ul><ul><ul><li>Combined: 1.4 (NNT = 2) </li></ul></ul><ul><ul><li>CBT: 0.97 (NNT = 3) </li></ul></ul><ul><ul><li>Sertraline: 0.67 (NNT = 6) </li></ul></ul>
  48. 48. Sertraline (2) 2% 21% Stomach ache 4% 21% Nausea 4% 12% Motor Overactivity 0% 7% Enuresis 4% 10% Diarrhea 0% 16% Decreased appetite PBO, N=28 SRT, N=56
  49. 49. Sertraline (2) <ul><li>Limits: </li></ul><ul><ul><li>Those assigned to CBT or combined group not blinded at all - expectancy effects </li></ul></ul><ul><ul><li>Sponsored by NIMH and Pfizer </li></ul></ul>
  50. 51. Meta-analysis <ul><li>Geller et al, 2003 </li></ul><ul><li>12 randomized controlled-trials </li></ul><ul><li>Included smaller studies, withdrawl design, cross-over design and active-comparator trials </li></ul>
  51. 52. Meta-analysis <ul><li>On CYBOCS: overall effect size of 0.47, statistically significant </li></ul><ul><li>No evidence of publication bias </li></ul><ul><li>Clomipramine had significantly more effect than SSRIs </li></ul><ul><li>SSRIs equal amongst each other </li></ul><ul><li>Fail-safe N of 973 </li></ul>
  52. 53. Conclusions <ul><li>Serotonin reuptake inhibitors are effective for pediatric OCD </li></ul><ul><li>Moderate effect size </li></ul><ul><li>Response rates: 30-60% </li></ul><ul><li>Common adverse events: insomnia, hyperkinesia, asthenia, diarrhea, nausea, weight loss </li></ul>
  53. 54. Future research <ul><li>Dosing </li></ul><ul><li>Length of treatment </li></ul><ul><li>Treatment resistant cases </li></ul><ul><li>CMI > SSRIs? </li></ul><ul><li>Safety: suicidal ideation, sexual side effects </li></ul>
  54. 55. References <ul><li>DeVeaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D., Fontaine, R., Greist, J.H., Reichler, R., Katz, R., Landau, P., Clomipramine Hydrochloride in Childhood and Adolescent Obsessive-Compulsive Disorder - a Multicenter Trial. J.Am. Acad. Child Adolesc. Psychiatry , 31:1, January 1992. 45-49 </li></ul>
  55. 56. References <ul><li>Geller, D., Hoog, S.L., Heiligenstein, J.H., Ricardi, R.K., Tamura, R., Kluszynski, S., Jacobson, J.G. Fluoxetine Treatment for Obsessive-Compulsive Disorder in Children and Adolescents: A Placebo-Controlled Clinical Trial. J. Am. Acad. Child Adolesc. Psychiatry , 40:7, July 2001, 773-779 </li></ul>
  56. 57. References <ul><li>Liebowitz, M.R., Turner, S.M., Piacentini, J., Beidel, D.C., Clarvit, S.R., Davies, S.O., Graae, F., Jaffer, M., Lin, S., Sallee, F.R., Schmidt, A., Simpson, H.B. Fluoxetine in Children and Adolescents with OCD: A Placebo-Controlled Trial. J. Am. Acad Child Adolesc Psychiatry 41:12, December, 2002, 1431-1438 </li></ul>
  57. 58. References <ul><li>Geller, D., Wagner, K., Emslie, G., Murphy, T., Carpenter, D.J., Wetherhold, E., Perera, P., Machin, A.,Gardiner, C. Paroxetine Treatment in Children and Adolescents with Obsessive-Compulsive Disorder: A Randomized, Multicenter, Double-Blind, Placebo-controlled Trial, J. Am. Acad. Child Adolesc. Psychiatry , 43:11, November 2004, 1387-1396 </li></ul>
  58. 59. References <ul><li>Riddle, M. A., Reeve, E. , Yaryura-Tobia, J.A., Yang, H., Claghorn, J.L., Gaffney, G., Greist, J.H., Holland, D.H., McConville, B.J., Pigott, T., Walkup, J.T., Fluvoxamine for Children and Adolescents with Obsessive-Compulsive Disorder: A Randomized, Controlled, Multicenter Trial, J.Am. Acad. Child Adolesc. Psychiatry , 40:2, February 2001, 222-229 </li></ul>
  59. 60. References <ul><li>March, J.S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E.H., Cutler, N.R., Dominguez, R., Ferguson, J., Muller, B., Riesenberg, R., Rosenthal, M., Sallee, F., Steiner, H, Wagner, K. Sertraline in Children and Adolescents with Obsessive-Compulsive Disorder. JAMA , 280: 20, November 1998, 1752-1756 </li></ul>
  60. 61. References <ul><li>Pediatric OCD Study Team: March, J., Foa, E. et al. Cognitive-Behavior Therapy, Sertraline and Their Combination for Children and Adolescents with Obsessive-Compulsive Disorder, JAMA , 292:16, October 2004, 1969-1976 </li></ul>
  61. 62. References <ul><li>Geller, D., Biederman, J., Stewart, S.E., Mullin, B., Martin, A., Spencer, T., Faraone, S., Which SSRI? A Meta-analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder, Am. J. Psychiatry 160:11, November 2003, 1919-1928 </li></ul>
  62. 63. Credits <ul><li>Principal Investigator, Producer, Music and Narration: Darren Courtney, M.D., B.Sc. </li></ul><ul><li>Supervisor: Dr. Clare Gray </li></ul><ul><li>Technical Support: Dr. Michael Cheng </li></ul><ul><li>Children’s Hospital of Eastern Ontario </li></ul>

×